A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · SINGLE
- Evidence population
- Human clinical study registration
- Participants
- 415
- Population
- ALL · 50 Years
- Duration
- 2018-09-12 to 2021-06-09
- Intervention
- PDS Implant filled with 100 mg/mL Ranibizumab; Intravitreal Injections of 10 mg/mL Ranibizumab
- Comparator
- Intravitreal Arm
- Outcomes measured
- Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score at the Average of Week 36 and Week 40, as Assessed Us…; Change From Baseline in BCVA Score Averaged Over Week 60 and Week 64 — Baseline, Week60, Week 64; Change From Baseline in BCVA Score Over Time — Baseline up to Week 96; Percentage of Participants With BCVA Score of 38 Letters (20/200 Approximate Snellen Equivalent) or Worse at the Averag…; Percentage of Participants With BCVA Score of 38 Letters (20/200 Approximate Snellen Equivalent) or Worse Over Time — B…; Percentage of Participants With BCVA Score of 69 Letters (20/40 Approximate Snellen Equivalent) or Better at the Averag…; Percentage of Participants With BCVA Score of 69 Letters (20/40 Approximate Snellen Equivalent) or Better Over Time — B…; Percentage of Participants Who Lose <10 or <5 Letters in BCVA Score From Baseline to the Average Over Week 36 and Week…; Percentage of Participants Who Lose <10 or <5 Letters in BCVA Score From Baseline Over Time — Baseline up to Week 96; Percentage of Participants Who Gain ≥0 Letters in BCVA Score From Baseline to the Average Over Week 36 and Week 40 — Ba…; Percentage of Participants Who Gain ≥0 Letters in BCVA Score From Baseline Over Time — Baseline up to Week 96; Change From Baseline in Center Point Thickness (CPT) at Week 36 — Baseline to Week 36; Change From Baseline in CPT Over Time — Baseline up to Week 96; Percentage of Participants in the PDS Implant Arm Who Undergo Supplemental Treatment With Intravitreal Ranibizumab 0.5…; Percentage of Participants in the PDS Implant Arm Who Undergo a Supplemental Treatment That Requires Subsequent Additio…; Percentage of Participants With Ocular and Systemic (Non-Ocular) AEs — Randomization to Week 96; Percentage of Participants With Adverse Events of Special Interest — Randomization to Week 96; Observed Serum Ranibizumab Concentrations at Specified Timepoints — Randomization to Week 96; Estimated PK Parameter Values AUC0-6M — Randomization to Week 96; Estimated PK Parameter Value t1/2 After PDS Implant Insertion — Randomization to Week 96
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.